Liver transplantation for HBV and management of reinfection

Torisu M, Yokoyama T, Amemiya H, et al.: Immunosuppression, liver injury, and hepatitis in renal, hepatic, and cardiac homograft recipients: with particular reference to the Australia antigen. Ann Surg 1971, 174:621–639. Davies SE, Portmann BC, O’Grady JG, et al.: Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991, 13:150–157. Todo S, Demetris AJ, Van Thiel D, et al.: Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 1991, 13:619–626. O’Grady JG, Smith HM, Davies SE, et al.: Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992, 14:104–111. Lau JY, Bain VG, Davies SE, et al.: High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992, 102:956–962. Starzl TE, Demetris AJ, Van Thiel D: Liver transplantation (2). N Engl J Med 1989, 321:1092–1099. Steinmuller T, Seehofer D, Rayes N, et al.: Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002, 35:1528–1535. Kim WR, Poterucha JJ, Kremers WK, et al.: Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004, 10:968–974. Samuel D, Muller R, Alexander G, et al.: Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993, 329:1842–1847. McMillan JS, Shaw T, Angus PW, et al.: Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995, 22:36–43. Tur-Kaspa R, Shaul Y, Moore DD, et al.: The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988, 167:630–633. Trautwein C, Shrem H, Tillmann HL, et al.: Hepatitis B virus mutations in the pre S genome before and after liver transplantation. Hepatology 1996, 24:482–488. Terrault NA, Zhiou S, McCory RW, et al.: Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998, 28:555–561. Grellier L, Mutimer D, Ahmed M, et al.: Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996, 348:1212–1215. Perrillo RP, Wright T, Rakela J, et al.: Multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001, 33:424–432. A large multicenter study that confirmed the lack of complete efficacy of lamivudine monotherapy as prophylaxis for viral recurrence following transplantation. Perrillo R, Rakela J, Dienstag J, et al.: Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999, 29:1581–1586. McGory RW, Ishitani MB, Oliveira WM, et al.: Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996, 61:1358–1364. Brind A, Jiang JJ, Samuel D, et al.: Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. J Hepatol 1997, 26:228–235. Gish RG, Keeffe EB, Lim J, et al.: Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. Hepatology 1995, 22:257–262. Samuel D, Kimmoun E: Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations. Clin Liver Dis 2003, 7:667–681. Terrault N, Holland C, Ferrell L, et al.: Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transpl Surg 1996, 2:132–138. Andreone P, Caraceni P, Grazi GL, et al.: Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998, 29:985–989. Nery JR, Weppler D, Rodriguez M, et al.: Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998, 65:1615–1621. Roche B, Samuel D, Roque AM, et al.: Lamivudine therapy for HBV infection after liver transplantation. J Hepatol 1999, 30(suppl_1):78. Balan V, Dodson FS, Vargas HE, et al.: Long-term follow up of lamivudine therapy for hepatitis B before and after liver transplantation; clinical implication of development of the YMDD mutant. Hepatology 1999, 30:346A. Malkan G, Cattral MS, Humar A, et al.: Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000, 69:1403–1407. Seehofer D, Rayes N, Berg T, et al.: Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Transpl Int 2000, 13:290–296. Fontana RJ, Hann HW, Wright T, et al.: A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001, 7:504–510. Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R: Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001, 7:113–117. Papatheodoridis GV, Sevastianos V, Burroughs AK: Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 2003, 3:250–258. Fontana RJ, Keeffe EB, Carey W, et al.: Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002, 8:433–439. This report clarified the role of lamivudine in patients with HBV and decompensated cirrhosis. Schiff ER, Lai CL, Hadziyannis S, et al.: Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003, 38:1419–1427. This large multicenter study clearly established the role of adefovir as salvage therapy for YMDD mutants in the transplant setting. Kruger M, Tillmann HL, Trautwein C, et al.: Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl Surg 1996, 2:253–262. Seehofer D, Rayes N, Bechstein WO, et al.: Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases. Z Gastroenterol 2000, 38:773–783. Rayes N, Seehofer D, Hopf U, et al.: Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplantation 2001, 71:96–101. Tillmann HL, Trautwein C, Bock T, et al.: Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999, 30:244–256. Pichoud C, Seigneres B, Wang Z, et al.: Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 1999, 29:230–237. Gish R, Lau J, Brooks L, et al.: Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996, 23:1–7. Bochet M, Tubiana R, Benhamou Y, et al.: Tenofovir disoproxil fumarate suppresses lamivudine-resistant HBV replication in patients coinfected with HIV/HBV. Paper presented at the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA; February 22–28, 2002. Rayes N, Seehofer D, Hopf U, et al.: Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplantation 2001, 71:96–101. Seigneres B, Pichoud C, Ahmed SS, et al.: Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. J Infect Dis 2000, 181:1221–1233. Mutimer D, Pillay D, Cook P, et al.: Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis 2000, 181:713–716. Seehofer D, Rayes N, Neuhaus R, et al.: Antiviral combination therapy for lamivudine resistant hepatitis B reinfection after liver transplantation. Transpl Int 2000, 13(suppl):S359-S362. Zoulim F: Treatment of pre- and post-liver transplantation HBV infection: should we aim at combination therapy? Hepatology 2003, 38:1353–1355. Roche B, Samuel D, Feray C, et al.: Retransplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience. Liver Transpl Surg 1999, 5:166–174. Lo CM, Cheung ST, Ng IO, et al.: Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. Liver Transpl 2004, 10:557–563. Chen CH, Chen PJ, Chu JS, et al.: Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation. Gastroenterology 1994, 107:1514–1518. McIvor C, Morton J, Bryant A, et al.: Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann Intern Med 1994, 121:274–275. Fang JW, Wright TL, Lau JY: Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B. Lancet 1993, 342:1175. Chan TM, Wu PC, Li FK, et al.: Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998, 115:177–181. Jamal H, Regenstein F, Farr G, et al.: Prolonged survival in fibrosing cholestatic hepatitis with long-term ganciclovir therapy. Am J Gastroenterol 1996, 91:1027–1030.